(Q36243701)

English

A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

2

object named as

Susan M Blaney

1 reference

Europe PubMed Central

13 August 2017

PMC publication ID

author name string

Julia Glade Bender

1

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Scott Borinstein

3

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Joel M Reid

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Sylvain Baruchel

5

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Charlotte Ahern

6

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Ashish M Ingle

7

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Darrell J Yamashiro

8

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Alice Chen

9

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Brenda Weigel

10

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Peter C Adamson

11

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Julie R Park

12

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

language of work or name

0 references

publication date

12 July 2012

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

Clinical Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

18

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

18

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

5081-5089

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

Molecular mechanisms and clinical applications of angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

Biomarkers of response and resistance to antiangiogenic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

Mechanisms of adverse effects of anti-VEGF therapy for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

Angiogenesis as a therapeutic target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

Regression of established tumors and metastases by potent vascular endothelial growth factor blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445751

1 October 2017

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22791883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantification of angiogenesis stimulators in children with solid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/22791883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resting and activated endothelial cells are increased in the peripheral blood of cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22791883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22791883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22791883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of serum vascular endothelial growth factor, endostatin, and leptin levels in children with lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22791883

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-12-0078

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36243701&oldid=2143377527"